A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer ; volume:180 ; number:1 ; day:17 ; month:1 ; year:2020 ; pages:135-146 ; date:2.2020
Breast cancer research and treatment ; 180, Heft 1 (17.1.2020), 135-146, 2.2020
- Urheber
-
Masuda, Norikazu
Ohtani, Shoichiro
Takano, Toshimi
Inoue, Kenichi
Suzuki, Eiji
Nakamura, Rikiya
Bando, Hiroko
Ito, Yoshinori
Ishida, Kazushige
Yamanaka, Takashi
Kuroi, Katsumasa
Yasojima, Hiroyuki
Kasai, Hiroi
Takasuka, Tsuyoshi
Sakurai, Takaki
Kataoka, Tatsuki R.
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-020-05524-6
- URN
-
urn:nbn:de:101:1-2020051520365176380431
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Masuda, Norikazu
- Ohtani, Shoichiro
- Takano, Toshimi
- Inoue, Kenichi
- Suzuki, Eiji
- Nakamura, Rikiya
- Bando, Hiroko
- Ito, Yoshinori
- Ishida, Kazushige
- Yamanaka, Takashi
- Kuroi, Katsumasa
- Yasojima, Hiroyuki
- Kasai, Hiroi
- Takasuka, Tsuyoshi
- Sakurai, Takaki
- Kataoka, Tatsuki R.
- Morita, Satoshi
- Ohno, Shinji
- Toi, Masakazu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer